Evidence map›Paper›PMID 33562571›Full record

ArticleInternational journal of molecular sciences2021

Evaluation of the Influence of Adalimumab on the Expression Profile of Leptin-Related Genes and Proteins in Keratinocytes Treated with Lipopolysaccharide A.

Beniamin Oskar Grabarek, Tomasz Kasela, Iwona Adwent, Barbara Zawidlak-Węgrzyńska, Ryszard Brus

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Effects of Adalimumab on Mitochondria of Psoriatic Mesenchymal Stem Cells.Journal of cellular and molecular medicine · 2025
    Article
  3. Article
  4. Article
  5. Endothelin-3 is epigenetically silenced in endometrioid endometrial cancer.Journal of cancer research and clinical oncology · 2023
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Beniamin Oskar GrabarekDepartment of Histology, Cytophysiology, and Embryology in Zabrze, Faculty of Medicine in Zabrze, The University of Technology in Katowice, 41-800 Zabrze, Poland.ORCID 0000-0003-1633-7145
Tomasz KaselaEuropean Center of Aestheticsin Katowice, 40-055 Katowice, Poland.
Iwona AdwentDepartment of Histology, Cytophysiology, and Embryology in Zabrze, Faculty of Medicine in Zabrze, The University of Technology in Katowice, 41-800 Zabrze, Poland.
Barbara Zawidlak-WęgrzyńskaDepartment of Chemistry in Zabrze, Faculty of Medicine in Zabrze, The University of Technology in Katowice, 41-800 Zabrze, Poland.
Ryszard BrusDepartment of Nursing and Maternity, High School of Strategic Planning in Dąbrowa Górnicza, 41-300 Dąbrowa Górnicza, Poland.
WSB University · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Psoriasis is a disease with a proinflammatory base, in which an increased expression of leptin, tumor necrosis factor alpha (TNF-α), interleukin (IL) IL-12/23, IL-6, is observed. A drug used in the treatment of psoriasis of moderate and acute strength is the monoclonal antibody anti-TNF-adalimumab. The goal of this study was to evaluate the influence of adalimumab on changes in the expression profile of leptin-related genes in human keratinocyte cells exposed to lipopolysaccharide A and analyze if adalimumab acts via leptin pathways. The evaluation of changes of the pattern of genes connected with leptin and proteins coded by them was marked in a culture of human keratinocytes (HaCaT) exposed to 1 µg/mL lipopolysaccharide A (LPS) for 8 h in order to induce the inflammatory process, then to 8 µg/mL of adalimumab for 2.8 and 24 h in comparison with the control (cells not treated with the substances). The techniques used were mRNA microarray, Real-Time Quantitative Reverse Transcription Reaction (RTqPCR), Enzyme-Linked Immunosorbent Assay (ELISA), as well as transfections of HaCaT culture with leptin small interfering RNA (siRNA) in order to see whether adalimumab works through pathways dependent on leptin. A statistically lower expression of leptin and its receptors was observed under the influence of the drug, independent of the exposition time of keratinocytes to adalimumab. In the cells transfected with leptin siRNA, a lower concentration of JAK2 and STAT3 proteins was observed, which confirms that adalimumab works through pathways dependent on leptin. Adalimumab has a modulatory effect on the gene expression pattern and the proteins coded by them connected with leptin in keratinocytes treated with LPS in vitro.

Indexed as

AdalimumabAnti-Inflammatory AgentsCaspasesCell LineHumansKeratinocytesLeptinLipopolysaccharidesPsoriasisReceptors, LeptinRNA, MessengerRNA, Small InterferingSignal TransductionTranscriptomeTumor Necrosis Factor-alphaTumor Necrosis Factor InhibitorsAdalimumabAnti-Inflammatory AgentsCaspasesLEP protein, humanLEPR protein, humanLeptinlipopolysaccharide ALipopolysaccharidesReceptors, LeptinRNA, MessengerRNA, Small InterferingTNF protein, humanTumor Necrosis Factor-alphaTumor Necrosis Factor Inhibitorsadalimumabkeratinocytesleptinlipopolysaccharide AmRNAsignaling pathwaysiRNA

Identifiers

PMID33562571
PMCPMC7915423
OpenAlexW3128482829

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.